|
     |
|
| ||
|
Product Status
OROS® Hydromorphone (NMED-1077) OROS® Hydromorphone has not been approved in the United States. The product is currently in Phase 3 clinical trials in the U.S. OROS® Hydromorphone has been approved in several European countries, and is being marketed in some of these countries by Janssen-Cilag under the name JurnistaTM. N-type calcium channel blockers Neuromed's oral N-type calcium channel blockers are investigational drug candidates. T-type calcium channel blockers Neuromed's oral T-type calcium channel blockers are investigational drug candidates. |
| ||||||
